Breaking News Instant updates and real-time market news.

IOVA

Iovance Biotherapeutics

$8.90

0.05 (0.56%)

, AZN

AstraZeneca

$33.42

0.3 (0.91%)

07:08
12/13/17
12/13
07:08
12/13/17
07:08

Iovance Biotherapeutics expands pipeline of TIL therapies into lung cancer

Iovance Biotherapeutics (IOVA) announced that patient enrollment has begun in a study combining TIL and nivolumab in advanced non-small cell lung cancer, or NSCLC, patients in collaboration with researchers at H. Lee Moffitt Cancer Center and Research Institute (Moffitt), Stand Up to Cancer and other partners. The company also announced that a Phase 2 study in PD-1/PDL-1 naive NSCLC patients, sponsored by Iovance, in collaboration with MedImmune, the global biologics research and development arm of AstraZeneca (AZN), will initiate in the first half of 2018. The study with MedImmune will allow for enrollment of NSCLC patients for treatment with LN-145 alone or in combination with durvalumab.

IOVA

Iovance Biotherapeutics

$8.90

0.05 (0.56%)

AZN

AstraZeneca

$33.42

0.3 (0.91%)

  • 13

    Dec

IOVA Iovance Biotherapeutics
$8.90

0.05 (0.56%)

08/03/17
OPCO
08/03/17
INITIATION
Target $13
OPCO
Outperform
Iovance Biotherapeutics initiated with an Outperform at Oppenheimer
Oppenheimer analyst Mark Breidenbach initiated Iovance Biotherapeutics with an Outperform and a $13 price target saying its tumor infiltrating lymphocytes therapy has been clinically validated by several academic institutions and expects to see a stream of clinical readouts from three ongoing company-sponsored trials in the next 12-18 month. Breidenbach expects lovance's path to commercialization in solid tumors to be simplified due to to the trailblazing of personalized CAR-T therapies for blood cancers.
08/31/17
HCWC
08/31/17
NO CHANGE
Target $16
HCWC
Buy
Iovance 'fired another shot across the bow of CAR-Ts,' says H.C. Wainwright
The approval of Novartis' (NVS) Kymriah is a "major leap forward" for oncology and immunotherapy, but there remains "significant room for differentiated products," H.C. Wainwright analyst Joseph Pantginis tells investors in a research note on Iovance Biotherapeutics (IOVA) titled "Pins Set Up: Kite Acquired and Kymriah Approved; TILs Can Knock 'Em Down; Reiterate Buy." The analyst believes Iovance's TILs, or tumor infiltrating lymphocytes, could be significantly differentiated from CAR-Ts like Kymriah. He says the TIL platform has a "significantly" more benign safety profile relative to CAR-Ts and growing evidence that it could effectively target solid tumors, an area where he thinks CAR-Ts continue to struggle. Pantginis thinks Iovance "fired another shot across the bow of CAR-Ts" with last night's ESMO conference abstracts. The company released preliminary data that it can generate highly active TILs from lymphoma tumors, the analyst contends. He reiterates a Buy rating on Iovance with a $16 price target. The shares closed yesterday down 30c to $5.55.
09/01/17
WELS
09/01/17
NO CHANGE
WELS
Outperform
Iovance fast track designation 'particularly validating,' says Wells Fargo
Wells Fargo analyst Jim Birchenough views Iovance Biotherapeutics' fast track designation from the FDA for its tumor infiltrating lymphocyte product LN-144 as "particularly validating for a novel cell therapy." The designation establishes unmet need for patients and could support a "more reasonable" Phase 3 hurdle, Birchenough tells investors in a research note. He has an Outperform rating on Iovance.
09/13/17
HCWC
09/13/17
NO CHANGE
Target $16
HCWC
Buy
Iovance expanding on multiple fronts, says H.C. Wainwright
Iovance Biotherapeutics released data at ESMO that it can generate highly active tumor infiltrating lymphocytes from lymphoma tumors, H.C. Wainwright analyst Joseph Pantginis tells investors in a research note titled "Targeting Liquid Tumors and Automating the Supply Chain; Iovance Expanding on Multiple Fronts." The analyst says that while clinical efficacy of these expanded TILs remains unknown, he sees "significant safety profile differentiation" when compared to CAR-Ts. He notes that Iovance is also building new partnerships to make the supply chain run more efficiently. Pantginis keeps a Buy rating on the shares with a $16 price target.
AZN AstraZeneca
$33.42

0.3 (0.91%)

11/13/17
BMOC
11/13/17
NO CHANGE
BMOC
BMO says Pfizer buying Biogen makes more sense than deal for Bristol-Myers
BMO Capital analyst Alex Arfaei noted the "significant market speculation" that Pfizer (PFE) is preparing to execute a large M&A deal. While many sources, including Bloomberg, have speculated that Pfizer could target Bristol-Myers (BMY), Arfaei argues that a deal for Biogen (BIIB) would make more sense. He believes Pfizer has a significant gap in neurology, particularly in Alzheimer's, where it cannot afford to remain on the sidelines as its peers - including Biogen, Merck (MRK), AstraZeneca (AZN), and Eli Lilly (LLY) - all have pivotal trials in that area reading out in 2019-2020. Pfizer could have an opportunity to leverage near-term volatility in Biogen's MS franchise to strike a deal during the next 6-9 months before a potential interim look on aducanumab, which Arfaei views as the strongest of the next wave of Alzheimer's drugs in development, he tells investors.
11/16/17
JEFF
11/16/17
NO CHANGE
JEFF
Buy
Jefferies names Roche new top global pick in Pharmaceuticals
Jefferies analyst Jeffrey Holford names Roche (RHHBY) his new "Top Pick Globally" in Pharmaceuticals following the strong share performance of his previous top pick for 2017, AbbVie (ABBV). The analyst believes the company's growth outlook is better than many investors think. Roche is nearing sentiment lows and investors "need to look hard at the replacement power" offered by assets Tecentriq, Ocrevus, Gazyva, ACE910 and Perjeta, Holford tells investors in a research note. Following Roche, the analyst has the highest conviction on Novartis (NVS), Bayer (BAYRY), AbbVie, Johnson & Johnson (JNJ), Zoetis (ZTS) and Eli Lilly (LLY). His least preferred stocks in Pharmaceuticals are Merck (MRK), Novo Nordisk (NVO) and AstraZeneca (AZN).
11/20/17
HCWC
11/20/17
NO CHANGE
Target $158
HCWC
Buy
Tesaro approval in Europe gives advantage over Lynparza, says H.C. Wainwright
H.C. Wainwright analyst Edward White said Tesaro's (TSRO) receipt of marketing authorization for Zejula in Europe will give the drug an immediate advantage over AstraZeneca's (AZN) Lynparza and should help Zejula capture significant share. White keeps a Buy rating and $158 price target on Tesaro shares.
12/05/17
DBAB
12/05/17
NO CHANGE
DBAB
Buy
AstraZeneca positioned to lead in ovarian cancer, says Deutsche Bank
Deutsche Bank analyst Richard Parkes believes recent "strong data" of Tagrisso/Imfinzi mark a turning point for AstraZeneca and the profitability of its lung cancer franchise. The analyst says his survey of 47 U.S. physicians treating patients with ovarian cancer suggests "strong uptake" of the PARP inhibitors class across multiple lines of therapy. Physicians perceive the various approved drugs as comparable on efficacy but with tolerability favoring AstraZeneca's Lynparza, Parkes tells investors in a research note. He believes AstraZeneca will emerge as market leader in a potential greater than $7B class, with "significant upside potential" to consensus forecasts. The analyst reiterates a Buy rating on the shares.

TODAY'S FREE FLY STORIES

SBRA

Sabra Health Care

$22.36

-0.17 (-0.75%)

09:28
07/17/18
07/17
09:28
07/17/18
09:28
Hot Stocks
Sabra, PointRight announce strategic partnership for post-acute analytics »

Sabra Health Care REIT…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECOR

ElectroCore

$14.49

-0.51 (-3.40%)

09:28
07/17/18
07/17
09:28
07/17/18
09:28
Initiation
ElectroCore initiated  »

ElectroCore initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HRC

Hill-Rom

$91.35

0.03 (0.03%)

09:28
07/17/18
07/17
09:28
07/17/18
09:28
Recommendations
Hill-Rom analyst commentary  »

Hill-Rom price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 14

    Aug

  • 15

    Aug

PM

Philip Morris

$81.91

-0.78 (-0.94%)

09:26
07/17/18
07/17
09:26
07/17/18
09:26
Recommendations
Philip Morris analyst commentary  »

Philip Morris estimates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

NFLX

Netflix

$400.24

4.32 (1.09%)

09:25
07/17/18
07/17
09:25
07/17/18
09:25
Recommendations
Netflix analyst commentary  »

Netflix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:25
07/17/18
07/17
09:25
07/17/18
09:25
General news
U.S. industrial production bounced 0.6% in June »

U.S. industrial…

09:25
07/17/18
07/17
09:25
07/17/18
09:25
General news
FX Action: The dollar »

FX Action: The dollar was…

09:25
07/17/18
07/17
09:25
07/17/18
09:25
Conference/Events
Stifel maritime analysts to hold an analyst/industry conference call »

Maritime Analysts, hosts…

MSI

Motorola Solutions

$121.33

0.54 (0.45%)

09:22
07/17/18
07/17
09:22
07/17/18
09:22
Hot Stocks
Motorola Solutions wins patent infringement lawsuit against Hytera Mobilfunk »

Motorola Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUTL

Autolus Therapeutics

$23.00

2.11 (10.10%)

09:21
07/17/18
07/17
09:21
07/17/18
09:21
Initiation
Autolus Therapeutics initiated  »

William Blair starts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$124.70

-1.24 (-0.98%)

09:20
07/17/18
07/17
09:20
07/17/18
09:20
Hot Stocks
Breaking Hot Stocks news story on Johnson & Johnson »

Johnson & Johnson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 08

    Aug

LULU

Lululemon

$127.21

1.8 (1.44%)

09:19
07/17/18
07/17
09:19
07/17/18
09:19
Recommendations
Lululemon analyst commentary  »

Lululemon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 18

    Jul

  • 19

    Jul

NVRO

Nevro

$58.79

1.04 (1.80%)

09:19
07/17/18
07/17
09:19
07/17/18
09:19
Recommendations
Nevro analyst commentary  »

Nevro risk/reward…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

TPGE

TPG Pace Energy

$11.55

-0.09 (-0.77%)

09:18
07/17/18
07/17
09:18
07/17/18
09:18
Hot Stocks
TPG Pace Energy shareholders approve combination with Enervest South Texas »

TPG Pace Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

09:18
07/17/18
07/17
09:18
07/17/18
09:18
Options
Overnight activity included 114 trades in SPX and 10 trades in VIX »

114 trades were executed…

SPX

S&P 500

$0.00

(0.00%)

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$356.01

5.2 (1.48%)

09:17
07/17/18
07/17
09:17
07/17/18
09:17
Hot Stocks
Boeing and Primera Air announce agreement »

Boeing and Primera Air…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

BKNG

Booking Holdings

$2,021.39

-10.06 (-0.50%)

09:16
07/17/18
07/17
09:16
07/17/18
09:16
Recommendations
Booking Holdings analyst commentary  »

Booking Holdings Q2 room…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

RMBS

Rambus

$12.69

0.13 (1.04%)

09:15
07/17/18
07/17
09:15
07/17/18
09:15
Hot Stocks
Rambus signs broad patent license agreement with Socionext »

Rambus announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

JNJ

Johnson & Johnson

$124.70

-1.24 (-0.98%)

09:15
07/17/18
07/17
09:15
07/17/18
09:15
Hot Stocks
Breaking Hot Stocks news story on Johnson & Johnson »

Johnson & Johnson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 08

    Aug

GOGO

Gogo

$3.75

-0.28 (-6.95%)

09:15
07/17/18
07/17
09:15
07/17/18
09:15
Downgrade
Gogo rating change  »

William Blair downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:15
07/17/18
07/17
09:15
07/17/18
09:15
General news
Fed Chairman Powell's Monetary Policy 10 ET testimony won't break new ground »

Fed Chairman…

RPD

Rapid7

$31.22

-0.48 (-1.51%)

, MSFT

Microsoft

$104.91

-0.51 (-0.48%)

09:13
07/17/18
07/17
09:13
07/17/18
09:13
Hot Stocks
Rapid7 integrates Insight platform with Microsoft Azure »

Rapid7 (RPD) announced…

RPD

Rapid7

$31.22

-0.48 (-1.51%)

MSFT

Microsoft

$104.91

-0.51 (-0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 06

    Aug

  • 08

    Aug

  • 08

    Aug

  • 04

    Sep

CMTL

Comtech

$34.54

-0.63 (-1.79%)

09:13
07/17/18
07/17
09:13
07/17/18
09:13
Hot Stocks
Comtech awarded $8M option for BFT-1 program contract »

Comtech announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RYCEY

Rolls-Royce

$0.00

(0.00%)

09:11
07/17/18
07/17
09:11
07/17/18
09:11
Periodicals
Rolls-Royce says stockpiling parts due to Brexit could start in Q4, Reuters says »

Rolls-Royce could begin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNH

UnitedHealth

$257.03

-1.69 (-0.65%)

09:11
07/17/18
07/17
09:11
07/17/18
09:11
Hot Stocks
UnitedHealth says more tailwinds than headwinds ahead »

Says Optum revenue grew…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.